Arcus Biosciences 数据日后启动增发、股价盘中已重挫约20%，盘后复盘无新增可交易 edge

Shares of Arcus Biosciences ( RCUS ), a late clinical-stage biopharmaceutical company, tumbled almost 20% on Wednesday, closing at $19.10 after falling $4.65 on the day. The decline came a day after the company presented new clinical data for its lead oncology candidate, casdatifan, across multiple kidney-cancer treatment lines. The company also commenced an underwritten public offering of its common stock. {"type": "symbol-chart", "props": {"ticker": "RCUS"}, "data": [{"symbol": {"id": 579079, "slug": "rcus", "name": "RCUS", "company": "Arcus Biosciences, Inc.", "company_name": "Arcus Biosciences, Inc.", "equity_type": "stocks", "fund_type_id": 0, "followers_count": 4848, "div_yield_type": "forward", "index_group": null, "is_bdc": false, "is_reit": false, "is_currency": false, "is_crypto": false, "is_mutual_funds": false, "is_etf": false, "is_cef": false, "is_index": false, "is_bond": false, "is_commodity": false}, "prices": {"id": 579079, "last": 19.065, "change": -4.684999999999999, "percent_change": -19.7263, "last_time": "2026-10-21T15:58:59.000-04:00", "high": 24.49, "low": 19.035, "open": 24.49, "prev_close": 23.75, "volume": 3510428.561786}, "ratings": {"quant_rating": 2.957222029788708, "sell_side_rating": 4.66667, "authors_rating": 4}, "key_data": {"last_close_price_earnings_ratio": null, "div_rate_fwd": null, "div_rate_ttm": null, "div_yield_fwd": null, "dividend_yield": null, "short_interest_shares_outstanding": 10.2962604242897, "marketcap": 3024167700, "impliedmarketcap": null, "estimate_eps": -3.5162, "diluted_eps_excl_extra_itmes": -3.864072, "estimate_ffo": null, "ffo_per_share_diluted": null, "pe_ratio_fwd": -6.75445082759798}}]} What Happened to Arcus Biosciences On October 20, Arcus announced new data from its ARC-20 platform evaluating casdatifan, an oral small-molecule HIF-2α inhibitor, alone and in combinations across first-, second-, and late-line clear cell renal cell carcinoma. The data included a 50% confirmed objective response rate in first-line patients treated with casdatifan plus zimberelimab, median progression-free survival of 14.5 months in second-line patients treated with casdatifan plus cabozantinib, and median progression-free survival of 13 months in late-line casdatifan monotherapy patients. By the Numbers: Arcus Biosciences Previous Close: $23.75 Today's Range: $19.035 – $24.49 (as of 3:58pm ET) 52-Week High: $31.74, roughly 40% above today's close 52-Week Low: $16.41, roughly 14% below today's close 50-Day Simple Moving Average: $26.71, approximately 11% above today's close 200-Day Simple Moving Average: $24.81, approximately 4% above today's close 14-Day RSI: 44.52, below the midpoint of the standard range Short Interest (% of Float): 14.48% Volume: approximately 3.51 million shares, about 2.03 times the one-month average Recent Stock Movement: Arcus Biosciences The table below showcases the stock's daily activity over the past few days: {"type": "table", "props": {"data": [{"date": "Oct 20, 2026", "return": "+7.27%"}, {"date": "Oct 19, 2026", "return": "+0.09%"}, {"date": "Oct 16, 2026", "return": "-3.07%"}, {"date": "Oct 15, 2026", "return": "+1.29%"}, {"date": "Oct 14, 2026", "return": "+0.09%"}, {"date": "Oct 13, 2026", "return": "-7.52%"}, {"date": "Oct 12, 2026", "return": "-0.29%"}, {"date": "Oct 9, 2026", "return": "+2.43%"}, {"date": "Oct 8, 2026", "return": "-2.81%"}, {"date": "Oct 7, 2026", "return": "+0.99%"}], "columns": [{"header": "Date", "accessor": "date", "align": "left"}, {"header": "Daily Return", "accessor": "return", "align": "right", "component": {"type": "signed-value"}}], "title": "RCUS Daily Returns"}} Latest Analyst Commentary on Arcus Biosciences Petri Dish Reports (October 21) described the ARC-20 casdatifan data as encouraging across first-line, second-line, and late-line kidney-cancer settings, while cautioning that the cohorts remain relatively small and that the results still require confirmation in randomized Phase 3 trials. The analysis carried a bullish rating but explicitly flagged clinical-execution and valuation risks as key uncertainties. Read more